AshHill Investments

AshHill Biomedical Investments operates as a private investment firm with a specialized focus on the biomedical sector. The firm commits capital to start-up, seed-stage, and established companies developing medical innovations, including pharmaceuticals and medical devices. Beyond financial backing, AshHill actively participates in its portfolio companies, offering strategic management, scientific guidance, and support services, leveraging deep industry expertise to foster growth and market entry.

The firm was founded in 2011 by Peter Milner, MD, who serves as its CEO. Dr. Milner, a cardiologist with a distinguished background as the founder of Optivia Biotechnology and CEO of Heart Metabolics, established AshHill with the insight that specialized, hands-on investment could significantly accelerate the development and commercialization of biomedical innovations. His extensive experience underpins the firm’s approach to active management.

AshHill primarily serves emerging and established companies within the biomedical landscape, guiding them through complex development and regulatory pathways. The firm's overarching mission is to optimize its investments by effectively bringing promising pharmaceuticals and medical devices through the necessary regulatory processes and into the broader marketplace, ultimately impacting patient care.